Locus
HOME
Corporate profile
Message
In 2001, Ohara Pharmaceutical was re-established and signed a strategic capital alliance with Itochu Chemical Frontier Corporation, Inabata & Co., Ltd., and CBC Co., Ltd. First, we selected and integrated projects. In response to the needs related to the current issues of an aging society and low birthrate, we commenced the centralization of management resources to support projects to produce high-quality and reliable generic drugs.
With "creation and coexistence" as our mission, and "Think Global, Act Locally" as our action policy, we will advance in the 21st century as a network corporation
The first period of a 3-year mid-term plan, called "Plan for the 21st century", incorporated the aspirations of all the staff and stakeholders. Thanks to everyone's support and encouragement, we were able to achieve stable business growth following the establishment of this plan.
After the completion of an additional mid-term plan, we have embarked upon the fourth period of the 3-year mid-term plan this fiscal year. In this low birthrate-aging society, there is an increasing need for a sustainable medical system and the stable provision of medical care. In order to realize a pharmaceutical industry capable of making a worthwhile contribution to society, Ohara Pharmaceutical will continue to promote generic products as a project which helps to reduce medical costs. Also, we have signed a license contract for Erwinase, which is a drug considered highly effective in the treatment of leukemia. We will continue our unflagging efforts as a pharmaceutical company which values the foundation upon which pharmaceutical companies are built, namely, to deliver medicines to those who are suffering from intractable diseases.
Please continue your support for Ohara Pharmaceutical in the years to come.
